Clinical Trial Update: Liposomal Irinotecan and Apatinib in ES-SCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating liposomal irinotecan in combination with apatinib for extensive-stage small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 2 | Status: RECRUITING